Amanda K A Silva, Marie Morille, Max Piffoux, Surendar Arumugam, Phlippe Mauduit, Jérôme Larghero, Arnaud Bianchi, Kelly Aubertin, Olivier Blanc-Brude, Danièle Noël, Emilie Velot, Célia Ravel, Céline Elie-Caille, Anna Sebbagh, Chantal Boulanger, Claire Wilhelm, Gabriel Rahmi, Isabelle Raymond-Letron, Kondareddy Cherukula, Tristan Montier, Christophe Martinaud, Jean-Marie Bach, Olivier Favre-Bulle, Jolanda Spadavecchia, Christian Jorgensen, Philippe Menasché, Clotilde Aussel, Joël Chopineau, Mathilde Mosser, Matti Ullah, Nicolas Sailliet, Nathalie Luciani, Noëlle Mathieu, Pierre-Emmanuel Rautou, Sophie Brouard, Wilfrid Boireau, Sébastien Jauliac, Marianne Dedier, Jean-Hugues Trouvin, Florence Gazeau, Marina Trouillas, Juliette Peltzer, Antoine Monsel, Sébastien Banzet
Extracellular vesicles (EV) are emergent therapeutic effectors that have reached clinical trial investigation. To translate EV-based therapeutic to clinic, the challenge is to demonstrate quality, safety, and efficacy, as required for any medicinal product. EV research translation into medicinal products is an exciting and challenging perspective. Recent papers, provide important guidance on regulatory aspects of pharmaceutical development, defining EVs for therapeutic applications and critical considerations for the development of potency tests...
December 2021: Advanced Drug Delivery Reviews